Pharmakokinetik

  • M. Freissmuth
Chapter
Part of the Springer-Lehrbuch book series (SLB)

Zusammenfassung

Pharmakokinetik beschreibt die Aufnahme (Absorption), Verteilung (Distribution), den Metabolismus und die Ausscheidung (Exkretion), abgekürzt ADME, von Pharmaka. Pharmaka können auch in tiefen Kompartimenten gespeichert werden. Erklärt werden in diesem Kapitel außerdem quantitative Parameter wie Halbwertszeit, Eliminationskonstante, Verteilungsvolumen, Clearance, Sättigungsdosis und Erhaltungsdosis, Kumulationsfaktor, absolute und relative Bioverfügbarkeit.

This is a preview of subscription content, log in to check access.

Weiterführende Literatur

  1. Daood M, Tsai C, Ahdab-Barmada M, Watchko JF (2008) ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 39: 211–218CrossRefPubMedGoogle Scholar
  2. Hines RN (2008) The ontogeny of drug metabolism and implications for adverse drug events. Pharmacol. & Ther 118: 250–267Google Scholar
  3. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH (2010) Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 70: 605–621CrossRefPubMedPubMedCentralGoogle Scholar
  4. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH (2008) Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 300: 2514–2526CrossRefPubMedPubMedCentralGoogle Scholar
  5. Kitamura S, Maeda K, Sugiyama Y (2008) Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans. Naunyn Schmiedebergs Arch Pharmacol 377: 617–628CrossRefPubMedGoogle Scholar
  6. Klaassen CD, Aleksunes, LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62: 1–96CrossRefPubMedPubMedCentralGoogle Scholar
  7. Kobayashi K, Hashimoto M, Honkakoski P, Negishi M (2015) Regulation of gene expression by CAR: an update. Arch Toxicol 89: 1045–1055CrossRefPubMedGoogle Scholar
  8. Kusuhara H, Sugiyama Y. (2009) In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24: 37–52CrossRefPubMedGoogle Scholar
  9. Strassburg CP, Lankisch TO, Manns MP, Ehmer U (2008) Family 1 uridine-5’-diphosphate glucuronosyltransferases (UGT1A): from Gilbert’s syndrome to genetic organization and variability. Arch Toxicol 82: 415–433CrossRefPubMedGoogle Scholar
  10. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ (1997) Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci USA 94: 8411–8416CrossRefPubMedPubMedCentralGoogle Scholar
  11. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41: 89–295CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • M. Freissmuth
    • 1
  1. 1.Zentrum für Physiologie und PharmakologieMedizinische Universität WienWienÖsterreich

Personalised recommendations